In Silico Development and Assessment of Hybrid Antimalarials as Falcipain Inhibitors
This study utilized in silico drug repurposing and rational hybrid design to identify and develop potent falcipain inhibitors for malaria treatment, demonstrating that combining high-affinity non-antimalarial compounds like Telithromycin with existing antimalarials yields superior hybrid candidates, particularly TELI-ATOVA, which warrants further experimental validation.